PCSK9 and cardiovascular disorder: PCSK9 inhibitors represent a breakthrough in the management of cardiovascular disease, offering a potent therapeutic option for lowering LDL cholesterol (LDL-C) and reducing cardiovascular risk, particularly in patients who are unable to tolerate statins[26].